PCM
TVTX icon

Pinz Capital Management’s Travere Therapeutics TVTX Stock Holding History

Pinz Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-91,700
Closed -$1.87M – 179
2020
Q2 		$1.87M Buy
+91,700
New +$1.46M 0.86% 51

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Pinz Capital Management's TVTX Position: Q3 2020 in Review

Pinz Capital Management sold out of Travere Therapeutics (TVTX) in Q3 2020, closing a stake of 91,700 shares — an estimated $1.87M sold.

Pinz Capital Management first reported a position in TVTX in Q2 2020 and held it in 1 quarter. The position peaked at $1.87M in Q2 2020. 134 funds tracked by Wall St. Rank hold TVTX as of Q3 2020.

  • Pinz Capital Management reported no remaining Travere Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Pinz Capital Management sold 91,700 Travere Therapeutics shares in Q3 2020, an estimated $1.87M.
  • Pinz Capital Management first reported a position in Travere Therapeutics in Q2 2020 and held it in 1 quarter.
  • Pinz Capital Management's Travere Therapeutics position peaked at $1.87M in Q2 2020.
  • 134 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2020.

Based on Pinz Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.